Joseph McEvoy

1.3k total citations · 1 hit paper
13 papers, 1.0k citations indexed

About

Joseph McEvoy is a scholar working on Psychiatry and Mental health, Philosophy and Economics and Econometrics. According to data from OpenAlex, Joseph McEvoy has authored 13 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Psychiatry and Mental health, 4 papers in Philosophy and 3 papers in Economics and Econometrics. Recurrent topics in Joseph McEvoy's work include Schizophrenia research and treatment (8 papers), Mental Health and Psychiatry (4 papers) and Health Systems, Economic Evaluations, Quality of Life (3 papers). Joseph McEvoy is often cited by papers focused on Schizophrenia research and treatment (8 papers), Mental Health and Psychiatry (4 papers) and Health Systems, Economic Evaluations, Quality of Life (3 papers). Joseph McEvoy collaborates with scholars based in United States. Joseph McEvoy's co-authors include T. Scott Stroup, Marvin S. Swartz, Richard S.E. Keefe, Jeffrey A. Lieberman, Robert A. Rosenheck, John Hsiao, Diana O. Perkins, Sonia M. Davis, Haiqun Lin and Edward Alan Miller and has published in prestigious journals such as American Journal of Psychiatry, Biological Psychiatry and The British Journal of Psychiatry.

In The Last Decade

Joseph McEvoy

12 papers receiving 980 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effectiveness of Clozapine Versus Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia Who Did Not Respond to Prior Atypical Antipsychotic Treatment

2006 650 citations Joseph McEvoy American Journal of Psychiatry profile →

Peers

Joseph McEvoy

PMH

PHILO

CP

EE

PHARM

Jonathan Thomas United States

Seema Quraishi United Kingdom

Monika Edlinger Austria

R. Tamura United States

Steve Offord United States

Danielle S. Abraham United States

Siow‐Ann Chong Singapore

Bin Fang China

O. Fleurot France

L. Kola Oyewumi Canada

Jonathan Thomas United States

Joseph McEvoy

551 ×0.7

PMH

209 ×0.8

PHILO

140 ×0.6

CP

113 ×0.8

EE

84 ×0.6

PHARM

Citations per year, relative to Joseph McEvoy Joseph McEvoy (= 1×) peers Jonathan Thomas

Countries citing papers authored by Joseph McEvoy

Since Specialization

Citations

This map shows the geographic impact of Joseph McEvoy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joseph McEvoy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joseph McEvoy more than expected).

Fields of papers citing papers by Joseph McEvoy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joseph McEvoy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joseph McEvoy. The network helps show where Joseph McEvoy may publish in the future.

Co-authorship network of co-authors of Joseph McEvoy

This figure shows the co-authorship network connecting the top 25 collaborators of Joseph McEvoy. A scholar is included among the top collaborators of Joseph McEvoy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joseph McEvoy. Joseph McEvoy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

1.

Mohamed, Somaia, Robert A. Rosenheck, Haiqun Lin, et al.. (2015). Randomized Trial of the Effect of Four Second-Generation Antipsychotics and One First-Generation Antipsychotic on Cigarette Smoking, Alcohol, and Drug Use in Chronic Schizophrenia. The Journal of Nervous and Mental Disease. 203(7). 486–492. 14 indexed citations

2.

McEvoy, Joseph, et al.. (2013). Clozapine for self-injurious behavior in individuals with borderline personality disorder. Therapeutic Advances in Psychopharmacology. 3(5). 272–274. 15 indexed citations

3.

Rosenheck, Robert A., Vicki G. Davis, Sonia M. Davis, et al.. (2009). Can a nonequivalent choice of dosing regimen bias the results of flexible dose double blind trials? The CATIE schizophrenia trial. Schizophrenia Research. 113(1). 12–18. 9 indexed citations

4.

Rosenheck, Robert A., Douglas Leslie, Jody L. Sindelar, et al.. (2006). Cost-Effectiveness of Second-Generation Antipsychotics and Perphenazine in a Randomized Trial of Treatment for Chronic Schizophrenia. American Journal of Psychiatry. 163(12). 2080–2089. 208 indexed citations

5.

McEvoy, Joseph. (2006). Effectiveness of Clozapine Versus Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia Who Did Not Respond to Prior Atypical Antipsychotic Treatment. American Journal of Psychiatry. 163(4). 600–600. 650 indexed citations breakdown →

6.

Rosenheck, Robert A., T. Scott Stroup, Richard S.E. Keefe, et al.. (2005). Measuring outcome priorities and preferences in people with schizophrenia. The British Journal of Psychiatry. 187(6). 529–536. 61 indexed citations

7.

Stroup, T. Scott, Paul S. Appelbaum, Marvin S. Swartz, et al.. (2005). Decision-making capacity for research participation among individuals in the CATIE schizophrenia trial. Schizophrenia Research. 80(1). 1–8. 68 indexed citations

8.

Marder, Stephen R., Dilip V. Jeste, & Joseph McEvoy. (1998). Atypical Antipsychotic Agents in the Treatment of Schizophrenia and Other Psychiatric Disorders. Part I: Unique Patient Populations. The Journal of Clinical Psychiatry. 59(5). 259–260. 2 indexed citations

9.

Keefe, R.S.E., et al.. (1998). Does autonoetic agnosia underlie specific psychotic symptoms in schizophrenia?. Schizophrenia Research. 29(1-2). 36–36. 1 indexed citations

10.

Keefe, Richard S.E., et al.. (1997). Self-monitoring deficits in schizophrenia: Autonoetic agnosia. Schizophrenia Research. 24(1-2). 110–110. 4 indexed citations

11.

Reynolds, Charles F., Jaspreet S. Brar, Patricia Houck, et al.. (1989). Sleep EEG changes in schizophrenia during haloperidol treatment. Biological Psychiatry. 25(7). A181–A181. 6 indexed citations

12.

Guy, William, et al.. (1983). A Double‐Blind Clinical Trial of Mianserin Versus Amitriptyline: Differentiation by Adverse Symptomatology. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 3(1). 45–51. 5 indexed citations

13.

McEvoy, Joseph, et al.. (1978). High circulating concentrations of glucagon in non-anaemic uraemic patients.. BMJ. 2(6129). 17–18.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact